



**Humana – CareSource®
2015 HEDIS Survey Results
Annual Rates**

Measure/Data Element	2015 Rate*	2015 National 50th Percentile
Effectiveness of Care: Prevention and Screening		
Adult BMI Assessment (ABA)	66.91%	83.45%
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)		
<i>BMI Percentile</i>	56.69%	67.23%
<i>Counseling for Nutrition</i>	49.64%	61.44%
<i>Counseling for Physical Activity</i>	47.20%	53.89%
Childhood Immunization Status (CIS)		
<i>DTaP</i>	64.23%	79.52%
<i>IPV</i>	77.86%	91.22%
<i>MMR</i>	86.62%	90.93%
<i>Hib</i>	82.00%	91%
<i>Hepatitis B</i>	69.83%	91.48%
<i>VZV</i>	86.37%	91.17%
<i>Pneumococcal Conjugate</i>	64.48%	79.88%
<i>Hepatitis A</i>	73.24%	84.43%
<i>Rotavirus</i>	55.72%	69.91%
<i>Influenza</i>	35.28%	51.43%
<i>Combination #2</i>	54.26%	75.47%
<i>Combination #3</i>	51.09%	71.53%
<i>Combination #4</i>	44.04%	67.64%
<i>Combination #5</i>	37.96%	58.36%
<i>Combination #6</i>	23.84%	43.65%
<i>Combination #7</i>	33.82%	55.52%
<i>Combination #8</i>	21.90%	42.23%
<i>Combination #9</i>	19.71%	36.68%
<i>Combination #10</i>	18.49%	35.88%
Immunizations for Adolescents (IMA)		
<i>Meningococcal</i>	69.83%	75.69%
<i>Tdap/Td</i>	71.78%	86.26%
<i>Combination #1</i>	67.15%	73.15%
Human Papillomavirus Vaccine for Female Adolescents (HPV)	13.25%	21.90%
Lead Screening in Children (LSC)	65.45%	71.93%
Breast Cancer Screening (BCS)	NA	NA
Cervical Cancer Screening (CCS)	35.52%	61.05%
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	6.37%	3.63%
Chlamydia Screening in Women (CHL)		
<i>16-20 Years</i>	55.93%	50.17%
<i>21-24 Years</i>	54.51%	61.21%
<i>Total</i>	55.02%	54.40%
Effectiveness of Care: Respiratory Conditions		
Appropriate Testing for Children with Pharyngitis (CWP)	78.39%	71.48%
Appropriate Treatment for Children With URI (URI)	80.35%	88.09%
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)	22.49%	26.30%
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	NA	NA
Pharmacotherapy Management of COPD Exacerbation (PCE)		
<i>Systemic Corticosteroid</i>	57.78%	69.01%
<i>Bronchodilator</i>	69.05%	83.43%

NA = Not applicable; Denominator fewer than 30
 NM = New Measure; No benchmark data
 *2015 Rates were extracted from the 2015 Interactive Data Submission System (IDSS) results.

**Humana – CareSource
2015 HEDIS Survey
Results Annual Rates**

Measure/Data Element	2015 Rate*	2015 National 50th Percentile
Use of Appropriate Medications for People With Asthma (ASM)		
5-11 Years	92.98%	91.23%
12-18 Years	92.54%	86.81%
19-50 Years	82.35%	74.16%
51-64 Years	NA	NA
Total	90.35%	84.54%
Medication Management for People With Asthma (MMA)		
5-11 Years - Medication Compliance 75%	43.40%	24.86%
12-18 Years - Medication Compliance 75%	30.65%	23.30%
19-50 Years - Medication Compliance 75%	NA	NA
51-64 Years - Medication Compliance 75%	NA	NA
Total - Medication Compliance 75%	38.35%	29.60%
Asthma Medication Ratio (AMR)		
5-11 Years	75.45%	70.41%
12-18 Years	56.72%	58.44%
19-50 Years	57.58%	48.28%
51-64 Years	NA	NA
Total	66.37%	60.76%
Effectiveness of Care: Cardiovascular Conditions		
Controlling High Blood Pressure (CBP)	50.61%	57.53%
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	79.73%	84.15%
Effectiveness of Care: Diabetes		
Comprehensive Diabetes Care (CDC)		
Hemoglobin A1c (HbA1c) Testing	88.87%	86.20%
HbA1c Poor Control (>9.0%)	66.97%	42.22%
HbA1c Control (<8.0%)	32.85%	47.91%
HbA1c Control (<7.0%)	21.67%	36.47%
Eye Exam (Retinal) Performed	39.96%	54.74%
Medical Attention for Nephropathy	84.49%	81.75%
Blood Pressure Control (<140/90 mm Hg)	49.09%	62.23%
Effectiveness of Care: Musculoskeletal Conditions		
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (ART)	60.91%	69.68%
Use of Imaging Studies for Low Back Pain (LBP)	56.97%	74.95%
Effectiveness of Care: Behavioral Health		
Antidepressant Medication Management (AMM)		
Effective Acute Phase Treatment	68.35%	50.51%
Effective Continuation Phase Treatment	59.71%	34.02%
Follow-Up Care for Children Prescribed ADHD Medication (ADD)		
Initiation Phase	42.28%	40.79%
Continuation and Maintenance (C&M) Phase	54.55%	50.61%
Follow-Up After Hospitalization for Mental Illness (FUH)		
30-Day Follow-Up	39.35%	66.64%
7-Day Follow-Up	20.99%	46.22%
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)	80.79%	80.10%
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	58.70%	69.61%
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	NA	NA
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	45.91%	60.68%

NA = Not applicable; Denominator fewer than 30

NM = New Measure; No benchmark data

*2015 Rates were extracted from the 2015 Interactive Data Submission System (IDSS) results.

**Humana – CareSource
2015 HEDIS Survey
Results Annual Rates**

Measure/Data Element	2015 Rate*	2015 National 50th Percentile
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)		
1-5 Years	NA	NM
6-11 Years	0.00%	NM
12-17 Years	0.00%	NM
Total	0.00%	NM
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)		
1-5 Years	NA	NM
6-11 Years	40.00%	NM
12-17 Years	41.76%	NM
Total	40.27%	NM
Effectiveness of Care: Medication Management		
Annual Monitoring for Patients on Persistent Medications (MPM)		
ACE Inhibitors or ARBs	90.02%	87.72%
Digoxin	50.00%	53.85%
Diuretics	90.36%	87.04%
Total	89.93%	87.05%
Access/Availability of Care		
Adults' Access to Preventive/Ambulatory Health Services (AAP)		
20-44 Years	72.68%	81.37%
45-64 Years	83.52%	87.84%
65+ Years	78.36%	87.52%
Total	77.16%	83.84%
Children and Adolescents' Access to Primary Care Practitioners (CAP)		
12-24 Months	92.39%	96.28%
25 Months - 6 Years	82.52%	88.46%
7-11 Years	88.32%	91.42%
12-19 Years	85.11%	90.06%
Annual Dental Visit (ADV)		
2-3 Years	38.65%	37.13%
4-6 Years	59.80%	60.71%
7-10 Years	54.91%	63.41%
11-14 Years	51.39%	59.61%
15-18 Years	42.99%	51.63%
19-21 Years	24.71%	34.43%
Total	46.40%	54.69%
Initiation and Engagement of AOD Dependence Treatment (IET)		
Initiation of AOD Treatment: 13-17 Years	47.50%	41.91%
Engagement of AOD Treatment: 13-17 Years	15.00%	14.99%
Initiation of AOD Treatment: 18+ Years	25.59%	37.61%
Engagement of AOD Treatment: 18+ Years	7.15%	9.83%
Initiation of AOD Treatment: Total	25.91%	38.03%
Engagement of AOD Treatment: Total	7.27%	10.07%
Prenatal and Postpartum Care (PPC)		
Timeliness of Prenatal Care	69.34%	85.19%
Postpartum Care	51.58%	62.77%
Call Answer Timeliness (CAT)	90.82%	85.37%
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)		
1-5 Years	NA	NM
6-11 Years	NA	NM
12-17 Years	55.56%	NM
Total	60.71%	NM

NA = Not applicable; Denominator fewer than 30

NM = New Measure; No benchmark data

*2015 Rates were extracted from the 2015 Interactive Data Submission System (IDSS) results.

**Humana – CareSource
2015 HEDIS Survey
Results Annual Rates**

Measure/Data Element	2015 Rate*	2015 National 50th Percentile
Utilization		
Frequency of Ongoing Prenatal Care (FPC)		
<i><21 Percent</i>	13.63%	8.63%
<i>21-40 Percent</i>	8.03%	59.49%
<i>41-60 Percent</i>	9.98%	5.62%
<i>61-80 Percent</i>	20.68%	7.82%
<i>81+ Percent</i>	47.45%	14.19%
Well-Child Visits in the First 15 Months of Life (W15)		
<i>0 Visits</i>	2.72%	1.65%
<i>1 Visit</i>	2.42%	1.86%
<i>2 Visits</i>	5.44%	3.10%
<i>3 Visits</i>	7.25%	5.09%
<i>4 Visits</i>	13.29%	9.58%
<i>5 Visits</i>	22.36%	17.82%
<i>6+ Visits</i>	46.53%	59.76%
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)		72.02%
Adolescent Well-Care Visits (AWC)		49.15%

NA = Not applicable; Denominator fewer than 30
 NM = New Measure; No benchmark data
 *2015 Rates were extracted from the 2015
 Interactive Data Submission System (IDSS) results.